Cyclobenzaprine HCl
Phase 3Small molecule
TakedaCyclobenzaprine HCl is one of 10 small molecule programs targeting Muscle spasm. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Muscle Spasm
#DrugCompanyPhaseTrials
1Nimbex
AbbVieApproved
Bayer Aspirin
BayerApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Esmeron
FFresenius Kabi Oncology Ltd.
Approved
Lioresal
NovartisPhase 2
Cyclobenzaprine Hydrochloride
NNeurana Pharmaceuticals, Inc.
Approved
Tolperisone
NNeurana Pharmaceuticals, Inc.
Phase 3
Cyclobenzaprine HCl
TakedaPhase 3
Calciferol
Alnylam PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cyclobenzaprine HCl. EMBL-EBI & Wellcome Sanger Institute.
- [4]